Barrington Research Cuts OPKO Health (NASDAQ:OPK) Price Target to $1.50

OPKO Health (NASDAQ:OPK) had its price objective reduced by Barrington Research from $2.25 to $1.50 in a research note issued to investors on Monday,Benzinga reports. Barrington Research currently has an outperform rating on the biotechnology company’s stock.

A number of other brokerages have also commented on OPK. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd. JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a report on Thursday, November 20th. They set a “neutral” rating for the company. Finally, Wall Street Zen raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Sunday, December 21st. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, OPKO Health currently has an average rating of “Hold” and an average target price of $2.03.

OPKO Health Trading Up 0.8%

NASDAQ OPK opened at $1.20 on Monday. The firm’s 50 day moving average price is $1.26 and its two-hundred day moving average price is $1.35. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.32 and a current ratio of 3.97. OPKO Health has a twelve month low of $1.11 and a twelve month high of $2.04. The stock has a market cap of $910.88 million, a price-to-earnings ratio of -4.00 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The business had revenue of $148.50 million during the quarter, compared to analysts’ expectations of $139.76 million. During the same quarter last year, the firm posted $0.01 earnings per share. OPKO Health’s revenue was down 19.1% compared to the same quarter last year. Equities analysts anticipate that OPKO Health will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Comerica Bank lifted its stake in shares of OPKO Health by 7.1% in the 4th quarter. Comerica Bank now owns 120,000 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 8,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in OPKO Health by 4.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 198,148 shares of the biotechnology company’s stock valued at $262,000 after buying an additional 8,954 shares in the last quarter. 360 Financial Inc. boosted its stake in shares of OPKO Health by 12.0% during the 2nd quarter. 360 Financial Inc. now owns 88,800 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 9,500 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of OPKO Health by 11.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 138,643 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 13,912 shares during the last quarter. Finally, Intech Investment Management LLC raised its stake in shares of OPKO Health by 11.4% in the 4th quarter. Intech Investment Management LLC now owns 159,652 shares of the biotechnology company’s stock valued at $201,000 after acquiring an additional 16,329 shares in the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.